Abstract
How prognostic and predictive factors might be used in breast cancer is intimately connected to the discussion of the treatment options available to patients today. Adjuvant therapy is only worthwhile if the improvement in outlook is great enough to more than balance the cost and toxicity of therapy. The questions to be addressed are not only whether adjuvant therapy should be given at all, but also which therapy. For example, would the incremental advantages of a given additional therapy justify its use. Basic adjuvant choices for estrogen receptor (ER)-positive and -negative patients are illustrated in Fig. 1.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Albain K, Green S, Osborne K, Cobau C, Levine E, Ingle J, Pritchard K, Schneider D, O’Sullivan J, Hess E, Martino S (1997) Tamoxifen (T) versus cyclophosphamide, adriamycin, and 5-FU plus either concurrent or sequential T in postmenopausal, receptor(+) node(+) breast cancer: a Southwest Oncology Group phase III intergroup trial (SWOG-8814, INT-0100). Proc Am Soc Clin Oncol 16:128a
American Society of Clinical Oncology (1996) Clinical practice guidelines of the use of tumor markers in breast and colorectal cancer. J Clin Oncol 14:2843–2877
Carlomagno C, Perrone F, Gallo C et al. (1996) c-erbB2 overexpression decreases the benefit of tamoxifen in early-stage breast cancer without axillary lymph node metastases. J Clin Oncol 14:2702–2708
Carter CL, Allen C, Henson DE (1989) Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer 63:181–187
Coates AS, Simes RJ (1992) Patients’ assessment of adjuvant treatment in operable breast cancer. In: Williams CS (ed) Introducing new treatments for cancer: practical, ethical, and legal problems. Wiley, New York, pp 448–458
Early Breast Cancer Trialists’ Collaborative Group (1992) Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet 339:1–15, 71-85
Elledge RM, Green S, Ciocca D, Pugh R, Allred DC, Clark GM, Hill J, Ravdin P, O’Sullivan J, Martino S, Osborne CK (1998) HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: a Southwest Oncology Group Study. Clin Cancer Res 4(1):7–12
Goldhirsch A, Wood WC, Senn H-J (1995) International consensus panel on the treatment of primary breast cancer. Eur J Cancer 31 A:1754–1759
Gusterson BA, Gelber RD, Goldhirsch A (1992) Prognostic importance of c-erbB-2 expession in breast cancer. International (Ludwig) Breast Cancer Study Group. J Clin Oncol 10:1049–1056
Muss HB, Thor A, Berry DA et al (1994) c-erbB-2 expression and S-phase activity predict response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med 330:1260–1266
Ravdin PM, Siminoff LA, Harvey JP (1998) What are American women told about their adjuvant therapy? J Clin Oncol 17:211–217
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1998 Springer-Verlag Berlin · Heidelberg
About this paper
Cite this paper
Ravdin, P.M. (1998). How Can Prognostic and Predictive Factors in Breast Cancer Be Used in a Practical Way Today?. In: Senn, HJ., Gelber, R.D., Goldhirsch, A., Thürlimann, B. (eds) Adjuvant Therapy of Primary Breast Cancer VI. Recent Results in Cancer Research, vol 152. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-45769-2_8
Download citation
DOI: https://doi.org/10.1007/978-3-642-45769-2_8
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-45771-5
Online ISBN: 978-3-642-45769-2
eBook Packages: Springer Book Archive